Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Differentiated Thyroid Cancer (DTC)

Conditions

Differentiated Thyroid Cancer (DTC)

Trial Timeline

Nov 15, 2021 → Jun 4, 2027

NCT ID

NCT04940052

About Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo

Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo is a phase 3 stage product being developed by Novartis for Differentiated Thyroid Cancer (DTC). The current trial status is active. This product is registered under clinical trial identifier NCT04940052. Target conditions include Differentiated Thyroid Cancer (DTC).

What happened to similar drugs?

1 of 7 similar drugs in Differentiated Thyroid Cancer (DTC) were approved

Approved (1) Terminated (1) Active (5)

🔄Abemaciclib + PlaceboEli LillyPhase 3

🔄Lenvatinib + PlaceboEisaiPhase 3

❌Selumetinib + Placebo + Radioactive Iodine TherapyAstraZenecaPhase 3

✅sunitinibPfizerApproved

🔄Vandetanib (SAR390530) + PlaceboSanofiPhase 3

🔄Thyrogen (thyrotropin alfa for injection)SanofiPhase 3

🔄Cabozantinib + PlaceboIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04940052	Phase 3	Active	Nov 15, 2021	Jun 4, 2027	Differentiated Thyroid Cancer (DTC)

Competing Products

20 competing products in Differentiated Thyroid Cancer (DTC)

See all competitors

Product	Company	Stage	Hype Score
CAB-AXL-ADC + PD-1 inhibitor	BioAtla	Phase 1/2	22
Abemaciclib + Placebo	Eli Lilly	Phase 3	44
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
Selpercatinib Monotherapy	Eli Lilly	Phase 2	42
Selumetinib + Placebo + Radioactive Iodine Therapy	AstraZeneca	Phase 3	32
Pembrolizumab + Cisplatin + Docetaxel + Carboplatin	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	42
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Everolimus + Sorafenib	Novartis	Phase 2	31
PDR001	Novartis	Phase 2	35
Everolimus (Afinitor®)	Novartis	Phase 2	35
Sacituzumab govitecan	Gilead Sciences	Phase 2	42
sunitinib	Pfizer	Approved	43
Vandetanib (SAR390530) + Placebo	Sanofi	Phase 3	40
Thyrogen (thyrotropin alfa for injection)	Sanofi	Phase 3	40
Cabazitaxel	Sanofi	Phase 2	35
Larotrectinib monotherapy	Bayer	Phase 2	39